TE
KROS icon

Tema ETFs’s Keros Therapeutics KROS Stock Holding History

Tema ETFs’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-35,663
Closed -$565K – 160
2024
Q4 		$565K Buy
+35,663
New +$1.85M 0.23% 92

Other funds holding KROS

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Tema ETFs's KROS Position: Q1 2025 in Review

Tema ETFs sold out of Keros Therapeutics (KROS) in Q1 2025, closing a stake of 35,663 shares — an estimated $565K sold.

Tema ETFs first reported a position in KROS in Q4 2024 and held it in 1 quarter. The position peaked at $565K in Q4 2024. 156 funds tracked by Wall St. Rank hold KROS as of Q1 2025.

  • Tema ETFs reported no remaining Keros Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Tema ETFs sold 35,663 Keros Therapeutics shares in Q1 2025, an estimated $565K.
  • Tema ETFs first reported a position in Keros Therapeutics in Q4 2024 and held it in 1 quarter.
  • Tema ETFs's Keros Therapeutics position peaked at $565K in Q4 2024.
  • 156 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2025.

Based on Tema ETFs's 13F filing for Q1 2025, filed 14 May 2025.